(4R)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (4R)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one
• 英文别名: 4-phenyl-3-(3-phenylprop-2-enoyl)-1,3-oxazolidin-2-one
• 化学式: C₁₈H₁₅NO₃
• 分子量: 293.322
• InChiKey: RJNZUERQMGKTAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4R)-4-phenyl-3-[(2E)-3-phenylprop-2-enoyl]-1,3-oxazolidin-2-one 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 以87%的产率得到N-(1-phenylvinyl)cinnamamide
  参考文献：
  名称：

  An efficient synthesis of styrenyl enamides from 4-aryl-2-oxazolidinones in the presence of strong base

  摘要：

  Efficient synthesis of styrenyl enamides can be achieved from the corresponding 4-aryl-2-oxazolidinones, 2-thioxooxazolidines, and 2-thioxothiazolidines in the presence of the strong base lithium diisopropylamine. The reaction proceeded efficiently to achieve the enamides in good to excellent yields (up to 92%). This reaction provides an easy, rapid, and good-yielding method for the synthesis of styrenyl enamides. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.08.026

文献信息

• [EN] N-PYRROLIDINYL, N'-PYRAZOLYL- UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-PYRROLIDINYLE, N'-PYRAZOLYL-URÉE, THIO-URÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078323A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.

  公式(I)的化合物或立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、环B和环C如本文所述定义，且环B和NH-C(=X)-NH基团处于反式构型，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些感染性疾病、舍格伦综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎或骨盆疼痛综合征。
• AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN
  申请人：ESTEVE PHARMACEUTICALS, S.A.

  公开号：EP3858439A1

  公开（公告）日：2021-08-04

  The present invention relates to new compounds that show pharmacological activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the µ-opiod receptor (MOR or mu-opioid). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments.

  本发明涉及对电压门控钙通道（VGCC）的亚单位α2δ，特别是对电压门控钙通道的α2δ-1亚单位或对电压门控钙通道（VGCC）的亚单位α2δ以及µ-阿片受体（MOR或μ-阿片）显示药理活性的新化合物。该发明还涉及所述化合物的制备方法，以及包含它们的组合物，以及它们作为药物的用途。
• [EN] SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] COMPOSES SPIRO ET PROCEDES POUR LA MODULATION DE L'ACTIVITE DE RECEPTEUR DE CHIMIOKINE
  申请人：VIROCHEM PHARMA INC

  公开号：WO2005023809A1

  公开（公告）日：2005-03-17

  Compounds of formula I insert formula I from claim 1 wherein X, Y, Z, W, R1 and R2 as defined herein, or pharmaceutically acceptable salts, hydrates or solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

  式I的化合物插入权利要求1中的式I，其中X、Y、Z、W、R1和R2如本文所定义，或其药用可接受的盐、水合物或溶剂化合物，可用于调节CCR5趋化因子受体活性。
• [EN] PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS<br/>[FR] COMPOSÉS DE N-PYRROLIDINYLE URÉE, THIO-URÉE,GUANIDINE ET CYANOGUANIDINE EN TANT QU'INHIBITEURS DE LA KINASE TRKA
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078378A1

  公开（公告）日：2014-05-22

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式（I）的化合物：或其立体异构体、互变异构体、药用可接受的盐、溶剂合物或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、环B和环C的定义如本文所述，其中环B基团和NH-C(=X)-NH基团处于反式构型，是TrkA激酶的抑制剂，并且可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、干燥综合症、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
  申请人：Kong Chan Chun Laval

  公开号：US20060014769A1

  公开（公告）日：2006-01-19

  Novel compounds represented by formula (I): wherein R 1 , R 2 , R 3 and R 4 are as defined herein, and pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity.

  由公式(I)表示的新化合物：其中R1、R2、R3和R4如本文所定义，并且其药用可接受盐、水合物和溶剂合物对于调节CCR5趋化因子受体活性是有用的。